LAB - Standard BioTools Inc. Stock Price, Fair Value and News

2.43USD+0.07 (+2.97%)Market Closed

Market Summary

USD2.43+0.07

Market Closed

2.97%

LAB Stock Price

View Fullscreen

LAB RSI Chart

LAB Valuation

Market Cap

920.6M

Price/Earnings (Trailing)

-12.33

Price/Sales (Trailing)

8.66

EV/EBITDA

-13.24

Price/Free Cashflow

-19.96

LAB Price/Sales (Trailing)

LAB Profitability

EBT Margin

-69.78%

Return on Equity

50.43%

Return on Assets

-23.11%

Free Cashflow Yield

-5.01%

LAB Fundamentals

LAB Revenue

Revenue (TTM)

106.3M

Rev. Growth (Yr)

4.32%

Rev. Growth (Qtr)

11.12%

LAB Earnings

Earnings (TTM)

-74.7M

Earnings Growth (Yr)

5.13%

Earnings Growth (Qtr)

5.82%

Breaking Down LAB Revenue

Last 7 days

-3.6%

Last 30 days

-9.7%

Last 90 days

2.5%

Trailing 12 Months

43.8%

How does LAB drawdown profile look like?

LAB Financial Health

Current Ratio

1.45

Debt/Equity

Debt/Cashflow

-76.08

LAB Investor Care

Shares Dilution (1Y)

381.69%

Diluted EPS (TTM)

-0.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	96.6M	105.5M	105.2M	106.3M
2022	124.3M	112.0M	109.2M	97.9M
2021	143.3M	148.3M	136.9M	130.6M
2020	114.7M	112.6M	126.0M	138.1M
2019	117.8M	119.6M	117.1M	117.2M
2018	101.7M	104.2M	108.4M	113.0M
2017	101.0M	96.7M	99.3M	101.9M
2016	117.0M	116.5M	110.1M	104.4M
2015	117.5M	118.5M	117.5M	114.7M
2014	82.4M	92.5M	103.8M	116.5M
2013	55.9M	60.5M	66.0M	71.2M
2012	45.1M	47.5M	49.7M	52.3M
2011	35.5M	38.1M	40.2M	42.9M
2010	0	28.1M	30.8M	33.6M
2009	0	0	0	25.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Standard BioTools Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	egholm michael	sold (taxes)	-277,948	2.71	-102,564	president & ceo
Apr 05, 2024	kim hanjoon alex	acquired	-	-	70,702	chief operating officer
Apr 05, 2024	egholm michael	acquired	-	-	212,126	president & ceo
Apr 04, 2024	egholm michael	acquired	-	-	196,512	president & ceo
Apr 04, 2024	kim hanjoon alex	acquired	-	-	70,183	chief operating officer
Mar 18, 2024	casdin partners master fund, l.p.	acquired	127,780,000	2.75	46,465,500	-
Mar 05, 2024	casdin partners master fund, l.p.	bought	3,668	2.615	1,403	-
Mar 04, 2024	casdin partners master fund, l.p.	bought	642,500	2.57	250,000	-
Feb 20, 2024	casdin eli	acquired	57,000	2.5	22,800	-
Jan 05, 2024	casdin eli	acquired	-	-	7,614	-

Which funds bought or sold LAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-	-	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	new	-	47,940	47,940	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	422	2,290	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-20.45	-5,972	237,395	-%
Apr 24, 2024	Assenagon Asset Management S.A.	added	783	1,422,810	1,567,570	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	317	2,385	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	49,306	49,306	-%
Apr 19, 2024	Evolution Wealth Advisors, LLC	new	-	33,089	33,089	0.01%
Apr 19, 2024	Sumitomo Mitsui Trust Holdings, Inc.	new	-	23,993,000	23,993,000	0.02%
Apr 18, 2024	ARK Investment Management LLC	new	-	35,345,000	35,345,000	0.24%

Are Funds Buying or Selling LAB?

Are funds buying LAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LAB

No. of Funds

Unveiling Standard BioTools Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 20, 2024	casdin capital, llc	16.19%	61,907,605	SC 13D/A
Mar 20, 2024	viking global investors lp	15.3%	58,651,170	SC 13G/A
Feb 26, 2024	millennium management llc	5.2%	15,037,065	SC 13G
Feb 14, 2024	indaba capital management, l.p.	9.9%	7,975,374	SC 13G/A
Feb 13, 2024	vanguard group inc	5.21%	4,133,939	SC 13G
Jan 12, 2024	neuberger berman group llc	1.51%	4,382,584	SC 13D/A
Jan 09, 2024	casdin capital, llc	16.17%	52,773,091	SC 13D/A
Jan 09, 2024	viking global investors lp	9.5%	29,106,365	SC 13G
Jan 08, 2024	caligan partners lp	2.4%	7,042,413	SC 13D/A
Nov 22, 2023	viking global investors lp	9.5%	8,289,116	SC 13D/A

Recent SEC filings of Standard BioTools Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	10-K/A	Annual Report
Apr 25, 2024	8-K	Current Report
Apr 09, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	3	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	SC 13D/A	13D - Major Acquisition

Standard BioTools Inc. News

Latest updates

Standard BioTools Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	11.1%	28,188,000	25,367,000	27,666,000	25,119,000	27,021,000	25,646,000	18,777,000	26,504,000	38,265,000	28,504,000	31,018,000	32,794,000	44,608,000	39,861,000	26,058,000	27,617,000	32,440,000	26,496,000	28,196,000	30,111,000	32,325,000
Gross Profit	19.8%	13,357,000	11,154,000	13,602,000	-	11,167,000	9,220,000	4,427,000	-	-	-	-	-	-	-	-	-	17,888,000	14,038,000	15,363,000	16,990,000	18,811,000
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27,854,000	29,999,000	31,196,000	81,244,000
Operating Expenses	-12.3%	28,352,000	32,326,000	31,051,000	41,712,000	25,145,500	38,247,000	42,990,000	54,007,000	49,524,000	48,116,000	48,286,000	52,114,000	61,512,000	45,325,000	39,784,000	42,559,000	41,621,000	40,312,000	42,832,000	44,317,000	-
S&GA Expenses	-6.5%	20,847,500	22,292,000	22,600,000	22,308,000	17,605,000	26,340,000	30,084,000	30,875,000	22,960,000	24,072,000	24,248,000	27,608,000	31,935,000	22,655,000	20,616,000	22,695,000	18,791,000	20,729,000	22,134,000	22,824,000	21,971,000
R&D Expenses	9.1%	6,947,000	6,370,000	6,184,000	6,409,000	7,425,000	8,486,000	12,606,000	8,865,000	8,541,000	9,209,000	9,441,000	10,753,000	11,186,000	8,128,000	8,448,000	8,699,000	8,278,000	7,125,000	7,865,000	8,372,000	7,958,000
EBITDA Margin	2.6%	-0.62	-0.63	-0.72	-1.29	-1.89	-1.60	-1.43	-0.90	-0.43	-0.46	-0.36	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-10.2%	1,098,000	1,223,000	1,129,000	1,117,000	1,190,000	1,049,000	1,062,000	1,030,000	1,072,000	968,000	896,000	887,000	890,000	885,000	897,000	900,000	643,000	444,000	491,000	2,701,000	4,069,000
Income Taxes	-446.0%	-173,000	50,000	300,000	300,000	70,000	-713,000	-1,613,000	-574,000	-818,500	-1,400,000	-500,000	-1,700,000	981,500	-200,000	-1,145,000	-680,000	354,000	-1,168,000	-1,143,000	42,000	-221,500
Earnings Before Taxes	4.8%	-19,938,000	-20,947,000	-16,739,000	-16,580,000	-20,775,000	-30,139,000	-65,152,000	-76,862,000	-10,243,000	-15,265,000	-17,660,000	-20,492,000	-17,039,000	-6,242,000	-14,160,000	-16,660,000	-12,331,000	-14,055,000	-14,896,000	-25,423,000	-15,015,000
EBT Margin	2.2%	-0.70	-0.71	-0.80	-1.37	-1.97	-1.67	-1.50	-0.97	-0.49	-0.51	-0.41	-	-	-	-	-	-	-	-	-	-
Net Income	5.8%	-19,776,000	-20,997,000	-17,040,000	-16,843,000	-20,845,000	-29,426,000	-63,539,000	-76,288,000	-9,429,500	-13,843,000	-17,143,000	-18,821,000	-18,026,000	-5,999,000	-13,015,000	-15,980,000	-12,685,000	-12,887,000	-13,753,000	-25,465,000	-14,775,000
Net Income Margin	2.5%	-0.70	-0.72	-0.80	-1.35	-1.94	-1.64	-1.46	-0.94	-0.45	-0.50	-0.40	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-14.8%	-14,139,000	-12,317,000	-10,167,000	-9,495,000	-19,936,000	-25,875,000	-30,926,000	-16,458,000	-7,465,000	-11,200,000	-18,836,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-4.8%	323	339	356	372	390	415	441	272	275	282	289	305	325	323	282	290	265	269	284	291	304
Current Assets	-7.3%	158	171	183	195	209	229	251	73.00	72.00	73.00	78.00	96.00	118	123	78.00	82.00	96.00	97.00	107	111	127
Cash Equivalents	-35.1%	52.00	80.00	142	114	81.00	61.00	75.00	31.00	29.00	30.00	32.00	51.00	70.00	73.00	44.00	36.00	24.00	28.00	26.00	66.00	95.00
Inventory	-6.4%	21.00	22.00	22.00	23.00	21.00	22.00	23.00	23.00	21.00	24.00	25.00	22.00	20.00	20.00	19.00	16.00	14.00	15.00	14.00	14.00	13.00
Net PPE	-1.4%	24.00	25.00	25.00	25.00	26.00	27.00	27.00	28.00	28.00	29.00	28.00	24.00	18.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	9.00
Goodwill	0.1%	106	106	106	106	106	106	106	106	106	106	106	106	107	106	106	2.00	104	104	104	104	104
Liabilities	0.1%	160	160	158	158	161	166	167	250	181	183	180	182	186	171	150	149	111	107	111	109	232
Current Liabilities	111.1%	109	52.00	47.00	44.00	43.00	46.00	43.00	47.00	50.00	47.00	53.00	54.00	54.00	43.00	38.00	35.00	33.00	33.00	37.00	34.00	38.00
Long Term Debt	-	1.00	-	-	-	55.00	-	-	36.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	55.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	1.00	-	-	-	55.00	-	-	36.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-148	-	-	-	-81.47	-	-	22.00	95.00	99.00	109	123	139	152	133	141	154	163	173	182	72.00
Retained Earnings	-2.0%	-1,000	-980	-959	-942	-926	-905	-875	-812	-736	-726	-712	-695	-676	-658	-652	-639	-623	-610	-598	-584	-558
Additional Paid-In Capital	0.5%	861	857	853	850	847	845	841	835	831	827	822	819	816	811	786	782	778	774	771	767	632
Shares Outstanding	1.0%	80.00	79.00	79.00	79.00	79.00	78.00	77.00	77.00	77.00	75.00	75.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	133	-	-	-	126	-	-	-	464	-	-	-	282	-	-	-	847	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-23.2%	-14,061	-11,412	-9,329	-8,485	-19,181	-24,611	-29,988	-15,590	-7,002	-9,494	-14,664	-12,901	-3,733	-4,599	-2,790	-4,295	-5,519	-4,548	-5,013	-20,130	-638
Share Based Compensation	2.6%	3,475	3,386	3,114	3,148	1,681	4,494	4,663	4,042	4,363	4,320	3,741	3,677	4,093	4,358	3,634	2,366	3,101	3,029	2,992	2,271	4,966
Cashflow From Investing	73.7%	-13,117	-49,926	40,126	43,154	40,245	10,736	-138,240	-868	-1,145	-1,706	-4,172	-4,923	-822	13,211	10,126	17,460	-551	6,549	-35,542	-9,757	-19.00
Cashflow From Financing	13.8%	-1,003	-1,164	-2,084	-2,558	-270	-5.00	212,958	18,075	7,297	9,821	-133	-1,026	432	20,417	511	-503	1,784	-181	1,040	147	59,952
Buy Backs	-60.1%	160	400	2,375	2,466	563	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

LAB Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 106,340	$ 97,948
Cost of revenue:
Total cost of revenue	55,890	60,897
Gross profit	50,450	37,051
Research and development	25,948	37,382
Selling, general and administrative	87,541	102,285
Restructuring and related charges	7,076	9,732
Transaction-related expenses	6,485	3,857
Total operating expenses	127,050	153,256
Loss from operations	(76,600)	(116,205)
Interest expense	(4,567)	(4,331)
Loss on forward sale of Series B Preferred Stock	0	(60,081)
Loss on Bridge Loans	0	(13,719)
Other income (expense), net	6,963	1,408
Loss before income taxes	(74,204)	(192,928)
Income tax benefit (expense)	(452)	2,830
Net loss	$ (74,656)	$ (190,098)
Net loss per share, basic (in dollars per share)	$ (0.94)	$ (2.43)
Net loss per share, diluted (in dollars per share)	$ (0.94)	$ (2.43)
Shares used in computing net loss per share, basic (in shares)	79,160	78,305
Shares used in computing net loss per share, diluted (in shares)	79,160	78,305
Service revenue
Revenue:
Total revenue	$ 25,980	$ 23,712
Product revenue
Revenue:
Total revenue	79,198	72,454
Cost of revenue:
Total cost of revenue	44,942	52,555
Service and other revenue
Revenue:
Total revenue	27,142	25,494
Cost of revenue:
Total cost of revenue	10,948	8,342
Other revenue
Revenue:
Total revenue	$ 1,162	$ 1,782

LAB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 51,704	$ 81,309
Short-term investments	63,191	84,475
Accounts receivable (net of allowances of $312 and $592 at December 31, 2023 and 2022, respectively)	19,660	17,280
Inventories, net	20,533	21,473
Prepaid expenses and other current assets	3,127	4,278
Total current assets	158,215	208,815
Property and equipment, net	24,187	25,652
Operating lease right-of-use asset, net	30,663	33,883
Other non-current assets	2,285	3,109
Developed technology, net	1,400	12,600
Goodwill	106,317	106,251
Total assets	323,067	390,310
Current liabilities:
Accounts payable	9,236	7,914
Accrued compensation and related benefits	11,867	9,153
Operating lease liabilities, current	4,323	3,682
Deferred revenue, current	11,607	10,792
Deferred grant income, current	3,612	3,644
Other accrued liabilities	9,152	6,175
Term loan, current	5,000	2,083
Convertible notes, current	54,530	0
Total current liabilities	109,327	43,443
Convertible notes, non-current	569	54,615
Term loan, non-current	3,414	8,194
Deferred tax liability	841	1,055
Operating lease liabilities, non-current	30,374	34,081
Deferred revenue, non-current	3,520	3,816
Deferred grant income, non-current	10,755	14,359
Other non-current liabilities	1,065	961
Total liabilities	159,865	160,524
Commitments and contingencies (Note 8)
Mezzanine equity:
Redeemable preferred stock: $0.001 par value; 256 shares authorized, issued and outstanding at December 31, 2023 and 2022; aggregate liquidation preference of $255,559 at December 31, 2023 and 2022	311,253	311,253
Stockholders' deficit:
Preferred stock: $0.001 par value, 9,744 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock: $0.001 par value, 400,000 shares authorized at December 31, 2023 and 2022; 83,364 and 79,904 shares issued at December 31, 2023 and 2022, respectively; 80,232 and 79,482 shares outstanding at December 31, 2023 and 2022, respectively	83	80
Additional paid-in capital	860,816	847,008
Accumulated other comprehensive loss	(2,221)	(1,896)
Accumulated deficit	(1,000,752)	(926,096)
Treasury stock at cost: 3,132 and 422 shares at December 31, 2023 and 2022, respectively	(5,977)	(563)
Total stockholders' deficit	(148,051)	(81,467)
Total liabilities, mezzanine equity and stockholders' deficit	$ 323,067	$ 390,310

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

CEO	Dr. Michael Egholm Ph.D.
WEBSITE	fluidigm.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	523

Standard BioTools Inc. Frequently Asked Questions

What is the ticker symbol for Standard BioTools Inc.? What does LAB stand for in stocks?

LAB is the stock ticker symbol of Standard BioTools Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Standard BioTools Inc. (LAB)?

As of Fri Apr 26 2024, market cap of Standard BioTools Inc. is 704.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LAB stock?

You can check LAB's fair value in chart for subscribers.

What is the fair value of LAB stock?

You can check LAB's fair value in chart for subscribers. The fair value of Standard BioTools Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Standard BioTools Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Standard BioTools Inc. a good stock to buy?

The fair value guage provides a quick view whether LAB is over valued or under valued. Whether Standard BioTools Inc. is cheap or expensive depends on the assumptions which impact Standard BioTools Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LAB.

What is Standard BioTools Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, LAB's PE ratio (Price to Earnings) is -9.44 and Price to Sales (PS) ratio is 6.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LAB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Standard BioTools Inc.'s stock?

In the past 10 years, Standard BioTools Inc. has provided -0.238 (multiply by 100 for percentage) rate of return.